The presence of circulating tumor DNA (ctDNA) at end of treatment (EOT) was shown to be prognostic of event-free survival (EFS) outcomes for patients with lymphoma regardless of subtype, according to findings from a retrospective, real-world…
Real-World Data Suggest ctDNA Status More Accurately Captures EFS Outcomes Than PET-CT
